US EditionEli Lilly launches its blockbuster weight loss drug Mounjaro in India
- Eli Lilly launched its weight-loss drug Mounjaro in India, becoming the first to enter a market troubled by rising obesity and diabetes rates.
- Mounjaro is priced at 4,375 rupees for a 5 mg vial, targeting India's growing obesity and diabetes crisis.
- A government survey indicated that 24 percent of women and nearly 23 percent of men aged 15 to 49 in India were overweight or obese from 2019 to 2021.
- Lilly faces competition not just from Novo Nordisk but also from Indian drugmakers seeking to produce generic versions of weight-loss medications.
24 Articles
24 Articles
Milind Deora slams weight-loss drug Mounjaro's launch, calls for higher sugar taxes
Rajya Sabha member Milind Deora has criticised the launch of Mounjaro in India. The weight-loss drug, developed by US-based Eli Lilly, is a weekly injectable medicine that costs Rs 3,500 for the 2.5 mg vial.
Eli Lilly's weight loss drug Mounjaro launched in India; check prices, how it works
Eli Lilly and Company launched its weight loss drug Mounjaro in India on Thursday after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). This is a drug which activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors which eventually help with obesity, overweight and type 2 diabetes. Price of Mounjaro in India According to the company, the injection is s…
Blockbuster weight-loss drug Mounjaro comes to India: How does it work?
Mounjaro, now launched in India, is the brand name of the drug called tirzepatide. Like its competitors Ozempic and Wegovy (brand names for the drug semaglutide), it is an injectable that needs to be used once a week. Experts say Mounjaro, which works by binding and activating two receptors – glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) – has shown incredible results when paired with diet and exercise w…
Coverage Details
Bias Distribution
- 56% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
